Cardioprotective role of insulin: Advantage analogues

Journal of Research in Medical Sciences

Volumn 17, Issue 7, 2012, Pages 642-648

  Maiti, Rituparna ^a   Jaida, Jyothirmai ^a   Leander, Pulukuri John Israel ^a   Irfanuddin, Mohammed ^a   Ahmed, Idris ^a   Palani, Anuradha ^a  

^a Prathima Institute of Medical Sciences   (India)

Author keywords

hsCRP; Insulin analogues; Regular human insulin; Type II diabetes mellitus; UKPDS 10 year CHD risk

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; INSULIN ASPART; INSULIN LISPRO; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 84866752559     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: Effects of oral anti-diabetic agents. Am J Cardiovasc Drugs 2005;5:201-9.
2. Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: Role of inflammation. Indian J Med Sci 2007;61:292-306.
3. Ciccone MM, Niccoli-Asabella A, Scicchitano P, Gesualdo M, Notaristefano A, Chieppa D, et al. Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease. Vasc Health Risk Manag 2011;7:129-34.
4. Elkeles RS. Coronary artery calcium and cardiovascular risk in diabetes. Atherosclerosis 2010;210:331-6.
5. Kereiakes DJ. The fire that burns within: C-reactive protein. Circulation 2003;107:373-4.
6. Yeh ET, Willerson JT. Coming age of C-reactive protein: Using inflammation markers in cardiology. Circulation 2003;107:370-2.
7. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, AndersonTJ, Verma S. New markers of inflammation and endothelial cell activation (part I). Circulation 2003;108:1917-23.
8. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation (part II). Circulation 2003;108:2041-8.
9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
10. Verma S, Szmitko PE, Yeh ET. C-reactive protein: Structure affects function. Circulation 2004;109:1914-7.
11. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55.
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
13. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
14. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: An update. Nat Rev Cardiol 2010;7:369-75.
15. Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, SimmonsDL, et al. Action to control cardiovascular risk in diabetes (ACCORD) investigators. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011;34:807-12.
16. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, LafontS, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.
17. Koskenkari JK, Kaukoranta PK, Rimpilainen J, Vainionpää V, Ohtonen PP, Surcel HM, et al. Anti-inflammatory effect of high- dose insulin treatment after urgent coronary revascularization surgery. Acta Anaesthesiol Scand 2006;50:962-9.
18. Jeemon P, Prabhakaran D, Ramakrishnan L, Gupta R, Ahmed F, Thankappan K, et al.; Sentinel Surveillance in Industrial Populations Study Group. Association of high sensitive C-reactive protein (hsCRP) with established cardiovascular risk factors in the Indian population. Nutr Metab (Lond) 2011;8:19.
19. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein associated increase in myocardial infarct size after ischemia/ reperfusion. J Pharmacol Exp Ther 2002;303:1007-13.
20. Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of Creactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. Life Sci 2004;75:901-10.
21. Reilly MP, Rader DJ. The metabolic syndrome; more than the sum of its parts? Circulation 2003;108:1546-51.
22. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000;85:2572-5.
23. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, PoweNR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
24. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol 2006;17:637-43.
25. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
26. Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007;7:228-34.
27. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-9.
28. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
29. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
30. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk Cohort. Diabetes Care 2009;32:708-13.
31. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NF kappa B and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001;86:450-3.
32. Wang CC, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 2003;52:2562-9.